These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2073118)

  • 41. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria.
    Lim VK; Halijah MY
    Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.
    Barry AL; Jones RN
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1830-2. PubMed ID: 2285302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
    Poudyal N; Gyawali N; Gurung R; Bhattarai NR; Baral R; Khanal B; Shrestha S; Amatya R; Bhattacharya SK
    Nepal Med Coll J; 2012 Mar; 14(1):5-8. PubMed ID: 23441486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ampicillin-sulbactam susceptibility testing criteria.
    Barry A; Pfaller M; Fuchs P; Gerlach E; Hardy D; McLaughlin J
    Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):469-72. PubMed ID: 8359171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
    Wang H; Chen MJ;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1991 Feb; 44(2):130-9. PubMed ID: 2041154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of eravacycline and cefoperazone/ sulbactam against extensively-drug resistant and pan-drug resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece.
    Meletis G; Protonotariou E; Gkeka I; Kassomenaki A; Mantzana P; Tychala A; Vlachodimou N; Kourti A; Skoura L
    New Microbiol; 2022 Jul; 45(3):210-212. PubMed ID: 35920876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response.
    Jones RN; Dudley MN
    Diagn Microbiol Infect Dis; 1997 May; 28(1):5-18. PubMed ID: 9218913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In-vitro activity of cefoperazone-sulbactam against Bacteroides species.
    Souza Dias MB; Jacobus NV; Tally FP
    J Antimicrob Chemother; 1986 Oct; 18(4):467-71. PubMed ID: 3021709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI; Farooqi BJ
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Basic and clinical evaluation of sulbactam/cefoperazone in the field of pediatrics].
    Toyonaga Y; Kurosu Y; Nakamura H; Sugita M; Takahashi T; Hori M
    Jpn J Antibiot; 1984 Dec; 37(12):2457-77. PubMed ID: 6098740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of beta-lactamase inhibitors on the potency of their companion drug with organisms possessing class I enzymes.
    Cavalieri SJ; Sanders CC; New C
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1343-7. PubMed ID: 1929291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.
    Crosby MA; Gump DW
    Antimicrob Agents Chemother; 1982 Sep; 22(3):398-405. PubMed ID: 6291451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
    Suzuki K; Horiba M
    Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
    Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [In vitro comparative activity of 4 beta-lactams against Pseudomonas aeruginosa. Role of cefoperazone].
    Joly-Guillou ML; Bergogne-Berezin E; Verin-Prevost C
    Pathol Biol (Paris); 1984 May; 32(5):408-11. PubMed ID: 6429612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.
    Jones RN; Barry AL
    J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.